Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 4.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,167,743 shares of the biopharmaceutical company's stock after purchasing an additional 50,804 shares during the period. Charles Schwab Investment Management Inc. owned about 0.98% of Catalyst Pharmaceuticals worth $23,215,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC bought a new position in Catalyst Pharmaceuticals during the second quarter worth $258,000. Integral Health Asset Management LLC acquired a new stake in Catalyst Pharmaceuticals during the second quarter worth approximately $4,260,000. GSA Capital Partners LLP bought a new stake in Catalyst Pharmaceuticals in the third quarter worth approximately $625,000. Allspring Global Investments Holdings LLC lifted its stake in Catalyst Pharmaceuticals by 146.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company's stock valued at $7,285,000 after buying an additional 217,956 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company's stock worth $46,479,000 after buying an additional 263,099 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 12,000 shares of the firm's stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now owns 51,391 shares of the company's stock, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Molly Harper sold 17,500 shares of the business's stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Citigroup raised their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Stephens started coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an "overweight" rating and a $35.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 9th. Finally, Truist Financial increased their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $31.14.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX traded up $0.32 during trading on Friday, hitting $22.02. The company had a trading volume of 535,632 shares, compared to its average volume of 1,178,282. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.00 and a 12 month high of $24.27. The firm has a market capitalization of $2.63 billion, a P/E ratio of 18.39, a price-to-earnings-growth ratio of 3.31 and a beta of 0.75. The stock has a 50 day simple moving average of $21.40 and a 200 day simple moving average of $18.91.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.